(2S,3R)-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-hydroxybutanamide | 1549792-00-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (2S,3R)-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-hydroxybutanamide
• 英文别名: US9987253, Example 2；(2S,3R)-2-[[[(4S)-5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-[(4-chlorophenyl)sulfonylamino]methylidene]amino]-3-hydroxybutanamide
• CAS: 1549792-00-8
• 化学式: C₂₆H₂₅Cl₂N₅O₄S
• 分子量: 574.488
• InChiKey: DJDOKEGYGRKFBK-AVIJNYRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide 在 五氯化磷 、 三乙胺 作用下， 以 二氯甲烷 、 氯苯 为溶剂， 反应 4.0h， 生成 (2S,3R)-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-hydroxybutanamide 、 (2S,3R)-2-((R)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-hydroxybutanamide
  参考文献：
  名称：

  [EN] CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS
  [FR] ANTAGONISTES/AGONISTES INVERSES DES RÉCEPTEURS DES CANNABINOÏDES

  摘要：

  本发明提供了新颖的、对映异构体的吡唑啉，其可用作大麻素受体阻滞剂及其药物组成物和使用它们治疗肥胖症、糖尿病、炎症性疾病、心代谢疾病、肝疾病和/或癌症的方法。

  公开号：

  WO2014018695A1

文献信息

• Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
  申请人：Jenrin Discovery, LLC

  公开号：US10617673B2

  公开（公告）日：2020-04-14

  The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.

  本发明提供了可用作大麻素受体阻断剂的新型非对映异构吡唑啉类化合物及其药物组合物，以及将其用于治疗肥胖症、糖尿病、炎症性疾病、心脏代谢疾病、肝脏疾病和/或癌症的方法。
• Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
  申请人：Jenrin Discovery, LLC

  公开号：US11179370B2

  公开（公告）日：2021-11-23

  The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.

  本发明提供了可用作大麻素受体阻断剂的新型非对映异构吡唑啉类化合物及其药物组合物，以及将其用于治疗肥胖症、糖尿病、炎症性疾病、心脏代谢疾病、肝脏疾病和/或癌症的方法。
• CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS AND CANCERS
  申请人：Jenrin Discovery

  公开号：US20140031404A1

  公开（公告）日：2014-01-30

  The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
• CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS AND CANCERS
  申请人：JENRIN DISCOVERY

  公开号：US20140329875A1

  公开（公告）日：2014-11-06

  The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
• CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES
  申请人：Jenrin Discovery

  公开号：US20160058736A1

  公开（公告）日：2016-03-03

  The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.